Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Status:
Completed
Trial end date:
2016-07-29
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate RLHFs concerning administration of the tocilizumab
autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving
subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle
safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be
assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and
healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining
study participants.